Wednesday, July 12, 2017 9:51:19 AM
RDI Initiates Coverage on:
TherapeuticsMD, Inc.https://ub.rdinvesting.com/news/?ticker=TXMD
Moleculin Biotech, Inc.https://ub.rdinvesting.com/news/?ticker=MBRX
TherapeuticsMD, Inc.'s shares closed in the green up 3.96% yesterday. Shares were up as much as 18.75% when the stock hit $5.70 during intra-day trading. The big move came after traders found out that an analyst at Oppenheimer upgraded the stock from "perform" to "outperform." He also gave shares a $10 price target which would be a major increase from current share prices. Jay Olson of Oppenheimer believes that there could be positive news from TherapeuticsMD's meeting with the FDA on or around the 14th of this month. According to Oppenheimer, the company will likely resubmit TX-004HR by the 31st and there could be a possible FDA approval by September 29. Olson says the probability of this is 60%. TX-004HR was rejected by the FDA a few months back as there were concerns that there was a lack of long-term endometrial safety data. TX-004HR is an investigational applicator-free estradiol vaginal soft gel capsule that is intended to treat moderate-to-severe vaginal pain.
Access RDI'sTherapeuticsMD, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=TXMD
Moleculin Biotech, Inc.'s shares closed up 8.45% on Tuesday despite any remarkable news. It was earlier this month however that the preclinical pharma company announced that it has appointed Dr. Lidia Gil from Poznan University of Medical Sciences in Poland to be the leader of its European Principal Investigator (PI) for the planned Phase I/II clinical trial of Annamycin. Annamycin is an anthracycline that is being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. CEO Walter Klemp commented, "Dr. Gil is a highly-respected hematologist-oncologist in Poland and we are honored to have her leading the European element of our upcoming clinical trial for Annamycin, which would commence only if our IND is permitted."
Dr. Gil Commented, "We are so pleased to be hosting the planned Annamycin clinical trial here in Poland. The absence of an approved second-line therapy for relapsed or refractory AML patients represents a significant unmet need and demonstrating activity in this trial could represent a major development in the treatment of AML."
It was also last month that the company announced that it has discovered a metabolic inhibitor with the potential to treat pancreatic cancer.
Access RDI'sMoleculin Biotech, Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=MBRX
Our Actionable Research on TherapeuticsMD, Inc. (NYSE:TXMD) and Moleculin Biotech, Inc. (NASDAQ:MBRX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@rdinvesting.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE:RDInvesting.com
This article appears in: News Headlines
Referenced Stocks: MBRX, TXMD
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
- Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
- Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
- Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
- Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
- Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/19/2024 02:06:59 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/16/2024 08:54:18 PM
- Moleculin Announces Pricing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/16/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:15 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 03:21:01 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 01:57:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:05:24 PM
- Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 01:05:10 PM
- Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET • PR Newswire (US) • 08/05/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:35:16 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM